Sorafenib in squamous cell carcinoma of the head and neck: Molecular basis and potential role

Future Oncology

Volumn 10, Issue 1, 2014, Pages 17-20

  Bhatt, Vijaya R ^a   Ganti, Apar Kishor ^a,b  

^a UNIVERSITY OF NEBRASKA MEDICAL CENTER   (United States)

^b VA NEBRASKA WESTERN IOWA HEALTH CARE SYSTEM   (United States)

Author keywords

biomarker; EGFR; neoadjuvant therapy; PDGF ; sorafenib; squamous cell carcinoma of the head and neck; VEGF

Indexed keywords

EPIDERMAL GROWTH FACTOR RECEPTOR; PLATELET DERIVED GROWTH FACTOR; SORAFENIB; VASCULOTROPIN; ANTINEOPLASTIC AGENT; CARBANILAMIDE DERIVATIVE; NICOTINAMIDE; PROTEIN KINASE INHIBITOR;

DISTANT METASTASIS; HEAD AND NECK SQUAMOUS CELL CARCINOMA; HUMAN; MOLECULAR BIOLOGY; MOLECULARLY TARGETED THERAPY; NOTE; PHASE 2 CLINICAL TRIAL (TOPIC); PRIORITY JOURNAL; TREATMENT RESPONSE; ANALOGS AND DERIVATIVES; CARCINOMA, SQUAMOUS CELL; HEAD AND NECK NEOPLASMS; METABOLISM;

ANTINEOPLASTIC AGENTS; CARCINOMA, SQUAMOUS CELL; HEAD AND NECK NEOPLASMS; HUMANS; NIACINAMIDE; PHENYLUREA COMPOUNDS; PROTEIN KINASE INHIBITORS;

EID: 84929876207     PISSN: 14796694     EISSN: 17448301     Source Type: Journal    
DOI: 10.2217/fon.13.212     Document Type: Note

References (22)

1. Jemal A, Bray F, Center MM, Ferlay J, Ward E, Forman D. Global cancer statistics. CA Cancer J. Clin. 61(2), 69-90 (2011).
2. Lee JM, Turini M, Botteman MF, Stephens JM, Pashos CL. Economic burden of head and neck cancer. A literature review. Eur. J. Health Econ. 5(1), 70-80 (2004).
3. Siegel R, Naishadham D, Jemal A. Cancer statistics, 2013. CA Cancer J. Clin. 63(1), 11-30 (2013).
4. Price KA, Cohen EE. Current treatment options for metastatic head and neck cancer. Curr. Treat. Options Oncol. 13(1), 35-46 (2012).
5. Thomas GR, Nadiminti H, Regalado J. Molecular predictors of clinical outcome in patients with head and neck squamous cell carcinoma. Int. J. Exp. Pathol. 86(6), 347-363 (2005).
6. Wilhelm SM, Adnane L, Newell P, Villanueva A, Llovet JM, Lynch M. Preclinical overview of sorafenib, a multikinase inhibitor that targets both Raf and VEGF and PDGF receptor tyrosine kinase signaling. Mol. Cancer Ther. 7(10), 3129-3140 (2008).
7. Alroy I, Yarden Y. The ErbB signaling network in embryogenesis and oncogenesis: signal diversification through combinatorial ligand-receptor interactions. FEBS Lett. 410(1), 83-86 (1997).
8. Guo P, Hu B, Gu W et al. Platelet-derived growth factor-B enhances glioma angiogenesis by stimulating vascular endothelial growth factor expression in tumor endothelia and by promoting pericyte recruitment. Am. J. Pathol. 162(4), 1083-1093 (2003).
9. Erber R, Thurnher A, Katsen AD et al. Combined inhibition of VEGF and PDGF signaling enforces tumor vessel regression by interfering with pericyte-mediated endothelial cell survival mechanisms. FASEB J. 18(2), 338-340 (2004).
10. Salomon DS, Brandt R, Ciardiello F, Normanno N. Epidermal growth factor-related peptides and their receptors in human malignancies. Crit. Rev. Oncol. Hematol. 19(3), 183-232 (1995).
11. Ongkeko WM, Altuna X, Weisman RA, Wang-Rodriguez J. Expression of protein tyrosine kinases in head and neck squamous cell carcinomas. Am. J. Clin. Pathol. 124(1), 71-76 (2005).
12. Gold KA, Lee HY, Kim ES. Targeted therapies in squamous cell carcinoma of the head and neck. Cancer 115(5), 922-935 (2009).
13. Iyer R, Fetterly G, Lugade A, Thanavala Y. Sorafenib: a clinical and pharmacologic review. Expert Opin. Pharmacother. 11(11), 1943-1955 (2010).
14. Liu L, Cao Y, Chen C et al. Sorafenib blocks the RAF/MEK/ERK pathway, inhibits tumor angiogenesis, and induces tumor cell apoptosis in hepatocellular carcinoma model PLC/PRF/5. Cancer Res. 66(24), 11851-11858 (2006).
15. Elser C, Siu LL, Winquist E et al. Phase II trial of sorafenib in patients with recurrent or metastatic squamous cell carcinoma of the head and neck or nasopharyngeal carcinoma. J. Clin. Oncol. 25(24), 3766-3773 (2007).
16. Blumenschein GR, Glisson BS, Lu C et al. Final results of a Phase II study of sorafenib in combination with carboplatin and paclitaxel in patients with metastatic or recurrent squamous cell cancer of the head and neck (SCCHN). ASCO Meeting Abstracts 30(15 Suppl.), Abstract 5592 (2012).
17. Williamson SK, Moon J, Huang CH et al. Phase II evaluation of sorafenib in advanced and metastatic squamous cell carcinoma of the head and neck: Southwest Oncology Group Study S0420. J. Clin. Oncol. 28(20), 3330-3335 (2010).
18. Cowey CL, Amin C, Pruthi RS et al. Neoadjuvant clinical trial with sorafenib for patients with stage II or higher renal cell carcinoma. J. Clin. Oncol. 28(9), 1502-1507 (2010).
19. Amin C, Wallen E, Pruthi RS, Calvo BF, Godley PA, Rathmell WK. Preoperative tyrosine kinase inhibition as an adjunct to debulking nephrectomy. Urology 72(4), 864-868 (2008).
20. Kondo T, Hashimoto Y, Kobayashi H et al. Presurgical targeted therapy with tyrosine kinase inhibitors for advanced renal cell carcinoma: clinical results and histopathological therapeutic effects. Jpn J. Clin. Oncol. 40(12), 1173-1179 (2010).
21. Margulis V, Matin SF, Tannir N et al. Surgical morbidity associated with administration of targeted molecular therapies before cytoreductive nephrectomy or resection of locally recurrent renal cell carcinoma. J. Urol. 180(1), 94-98 (2008).
22. Thomas AA, Rini BI, Stephenson AJ et al. Surgical resection of renal cell carcinoma after targeted therapy. J. Urol. 182(3), 881-886 (2009).